TCG Crossover Management, LLC
TCG Crossover Management, LLC reported 57 holdings worth US$3.54B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
TCG Crossover Management, LLC reported 57 holdings worth US$3.54B as of Sep 30, 2026. Largest: Abivax SA, CG Oncology, Inc. and Amylyx Pharmaceuticals, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 57
- Value as reported
- US$3.54B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Abivax SA | 3.66M | US$363M | 10.2% |
| CG Oncology, Inc. | 3.67M | US$260M | 7.4% |
| Amylyx Pharmaceuticals, Inc. | 6.24M | US$182M | 5.1% |
| Spyre Therapeutics, Inc. | 1.9M | US$169M | 4.8% |
| Tango Therapeutics, Inc. | 6.77M | US$169M | 4.8% |
| Zai Lab Ltd. | 6.23M | US$164M | 4.6% |
| Immunovant, Inc. | 4.46M | US$151M | 4.3% |
| Dianthus Therapeutics, Inc. | 1.68M | US$148M | 4.2% |
| Kodiak Sciences Inc | 1.45M | US$137M | 3.9% |
| Vor Biopharma Inc. | 5.67M | US$108M | 3.1% |
| First Tracks Biotherapeutics, Inc. | 2.9M | US$103M | 2.9% |
| Mirum Pharmaceuticals, Inc. | 1.12M | US$95.6M | 2.7% |
| BioCryst Pharmaceuticals, Inc. | 11M | US$91.8M | 2.6% |
| Disc Medicine, Inc. | 1.34M | US$87.8M | 2.5% |
| ADARx Pharmaceuticals, Inc. | 4.12M | US$82.1M | 2.3% |
| Cogent Biosciences, Inc. | 2.5M | US$80.1M | 2.3% |
| Tyra Biosciences, Inc. | 3.48M | US$76M | 2.1% |
| Dyne Therapeutics, Inc. | 4.62M | US$74.3M | 2.1% |
| Relay Therapeutics, Inc. | 3.78M | US$68.3M | 1.9% |
| Aura Biosciences, Inc. | 10.2M | US$63.8M | 1.8% |
| Savara, Inc. | 12.4M | US$63.8M | 1.8% |
| Xencor, Inc. | 2.06M | US$51.3M | 1.4% |
| Avalo Therapeutics, Inc. | 3.02M | US$46.3M | 1.3% |
| Monte Rosa Therapeutics, Inc. | 3.78M | US$45.1M | 1.3% |
| MBX Biosciences, Inc. | 650K | US$38.1M | 1.1% |
| Janux Therapeutics, Inc. | 1.79M | US$30.9M | 0.87% |
| Tarsus Pharmaceuticals, Inc. | 388K | US$30.5M | 0.86% |
| Century Therapeutics, Inc. | 17.8M | US$30.4M | 0.86% |
| Obsidian Therapeutics, Inc. | 2.2M | US$30.2M | 0.85% |
| LB Pharmaceuticals Inc | 765K | US$29.4M | 0.83% |
| Editas Medicine, Inc. | 11.1M | US$28.6M | 0.81% |
| Tectonic Therapeutic, Inc. | 1.2M | US$28.1M | 0.79% |
| Perspective Therapeutics, Inc. | 7.92M | US$21.8M | 0.61% |
| AgomAb Therapeutics NV | 1.82M | US$20.2M | 0.57% |
| Silence Therapeutics PLC | 1.82M | US$19.9M | 0.56% |
| Alector, Inc. | 10M | US$18.5M | 0.52% |
| Biohaven Ltd. | 1.26M | US$16.9M | 0.48% |
| Monopar Therapeutics Inc. | 202K | US$16.1M | 0.46% |
| Entrada Therapeutics, Inc. | 1.06M | US$6.73M | 0.19% |
| Cullinan Therapeutics, Inc. | 407K | US$6.24M | 0.18% |
| Agenus Inc. | 604K | US$6M | 0.17% |
| Ocular Therapeutix, Inc. | 720K | US$5.52M | 0.16% |
| Arvinas, Inc. | 707K | US$5.47M | 0.15% |
| Korro Bio, Inc. | 416K | US$4.13M | 0.12% |
| Research Alliance Corporation IV | 300K | US$3.6M | 0.10% |
| ALX Oncology Holdings Inc. | 2.47M | US$3.43M | 0.10% |
| Aktis Oncology, Inc. | 133K | US$2.6M | 0.07% |
| JATT II Acquisition Corp | 200K | US$2.25M | 0.06% |
| LeonaBio, Inc. | 464K | US$1.66M | 0.05% |
| JATT III Acquisition Corp | 100K | US$1.1M | 0.03% |
| Context Therapeutics Inc. | 2.68M | US$806K | 0.02% |
| Eikon Therapeutics, Inc. | 37,902 | US$305K | <0.01% |
| Research Alliance Corporation III | 0 | US$0 | 0.00% |
| Revolution Medicines, Inc. | 0 | US$0 | 0.00% |
| Surrozen, Inc. | 0 | US$0 | 0.00% |
| Altimmune, Inc. | 0 | US$0 | 0.00% |
| Forte Biosciences, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related